Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cassiopea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Receives FDA Approval for Winlevi\u00ae (clascoterone Cream 1%)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Curia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia Named Exclusive API Supplier for Recently Approved Acne Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"$45.0 million","newsHeadline":"Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Presents Phase 3 Data for WINLEVI\u00ae (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI\u00ae to include Japan, Australia, New Zealand, Brazil, Mexico and Russia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Cosmo and Glenmark Announce the Signing of Distribution and License Agreements for Winlevi\u00ae in Europe and South Africa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Cassiopea

    Menu

    Cassiopea

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cassiopea

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cosmo and Glenmark Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

              Details:

              Under the agreements, Glenmark will receive from Cassiopea, the exclusive right to commercialize Winlevi (clascoterone cream), used on the skin (topical) to treat acne vulgaris in people 12 years of age and older, in 15 EU countries as well as in South Africa and the UK.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: $5.0 million

              Deal Type: Licensing Agreement September 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia

              Details:

              Under the terms of the above referred agreements, Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI (clascoterone) in Japan, Australia, New Zealand, Brazil, Mexico and Russia.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

              Deal Size: Undisclosed Upfront Cash: $7.0 million

              Deal Type: Licensing Agreement July 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting

              Details:

              Results from two pivotal clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne)showed favorable safety and efficacy data for WINLEVI in patients with acne aged 12 years and older.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sun Pharmaceutical Industries Limited

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi®

              Details:

              Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi® in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

              Deal Size: $235.0 million Upfront Cash: $45.0 million

              Deal Type: Licensing Agreement July 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

              Details:

              Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Curia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cassiopea Receives FDA Approval for Winlevi® (clascoterone Cream 1%)

              Details:

              Winlevi (clascoterone cream 1%) is approved for the treatment of acne vulgaris in people aged 12 and older. In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day.

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: Winlevi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cassiopea

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne

              Details:

              The study demonstrated that Clascoterone cream 1%, has favorable long-term safety for the treatment of acne with low rates of treatment related adverse events (AEs).

              Lead Product(s): Clascoterone

              Therapeutic Area: Dermatology Product Name: CB-03-01

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY